What's Happening?
Gator Bio, a company specializing in biolayer interferometry (BLI) systems, and Hudson Lab Automation have introduced a new integrated automation solution aimed at enhancing high-throughput antibody discovery and characterization. This development was showcased at the SLAS conference. The collaboration between the two companies has resulted in the Gator Bio Pivot and Pro BLI systems being integrated with Hudson's PlateCrane automation platform. This integration significantly boosts sample throughput, increasing capacity from 400 to over 1,200 samples per day, depending on the workflow configuration. This advancement addresses a major bottleneck in scaling antibody discovery programs, especially for those utilizing AI-designed antibody libraries
that produce thousands of candidates needing rapid characterization. The solution targets applications such as high throughput hybridoma and yeast display screening, affinity ranking, epitope binning, and full kinetic characterization for lead optimization, among others.
Why It's Important?
The introduction of this automation solution is significant for the biotechnology industry, particularly in the field of antibody discovery. By tripling the sample throughput capacity, the solution allows for more efficient processing of large volumes of samples, which is crucial for organizations working with AI-designed antibody libraries. This can lead to faster development and optimization of antibodies, potentially accelerating the timeline for bringing new therapies to market. The ability to handle large antibody panels and perform detailed characterizations efficiently can enhance research and development efforts, ultimately benefiting pharmaceutical companies and healthcare providers by providing more effective treatments. The collaboration between Gator Bio and Hudson Lab Automation exemplifies the growing trend of integrating advanced technologies to overcome existing limitations in biotechnological research.
What's Next?
Following the demonstration of the integrated platform at the Antibody Engineering & Therapeutics conference, it is expected that Gator Bio and Hudson Lab Automation will continue to refine and promote their solution to a broader audience within the biotechnology sector. As organizations adopt this technology, there may be increased interest in further automating other aspects of the antibody discovery process. Additionally, the success of this collaboration could inspire similar partnerships aimed at integrating cutting-edge technologies to address other bottlenecks in the field. Stakeholders in the biotechnology industry, including researchers and pharmaceutical companies, will likely monitor the adoption and performance of this solution closely.
